DOW Module 1 Midpoint Quiz

A vibrant and informative illustration depicting breast cancer awareness ribbons, various treatment options including medications and therapies, and a healthcare professional discussing treatment strategies with a patient in a clinical setting.

Breast Cancer Treatment Insights Quiz

Welcome to the Breast Cancer Treatment Insights Quiz! This quiz is designed to test your knowledge on important topics related to breast cancer staging, treatment options, and drug mechanisms. Whether you are a healthcare professional, student, or simply someone interested in oncology, this quiz will enhance your understanding of effective strategies in breast cancer care.

Key Topics Include:

Breast cancer staging and therapy goals
Hormone receptor statuses and their implications
Specific regimens and their administration

10 Questions2 MinutesCreated by CaringDoctor254

Breast cancer staging helps to define:

Severity of disease

Goals of therapy

Location of disease in the body

All of the above

Progesterone status often is related to HER2 status.

True

False

True or False: Enhertu should be mixed in PPR. Explain your answer.

Which of the following is true?

CMF is a low-emetogenic regimen.

In CMF, cyclophosphamide is dosed at 400mg/m2

Methotrexate can cause GI toxicity

CMF is preferred as first line therapy.

For which of the following receptor statuses is Faslodex appropriate?

HR(-) HER2(-)

HR(-) HER2(+)

HR(+) HER2(+)

HR(+) HER2(-)

Trastuzumab (Herceptin) is ONLY indicated for HER2+ breast cancer.

True

False

Which of the following is dosed at 3.6 mg/kg every 3 weeks?

Enhertu

Kadcyla

Trodelvy

Padcev

True or False: Enhertu is given until progression free survival.

True

False

AB is scheduled to begin Trodelvy C1D1 on 10/22. On what day should AB receive Neulasta OBI?

10/22

10/23

10/29

10/30

Which regimen matches the following description: 1. Is a preferred regimen to treat early-stage, triple negative breast cancer. 2. Can be given as a neoadjuvant or adjuvant therapy 3. Requires monitoring for cardiotoxicity 4. Requires dose adjustment for hepatic dysfunction

Herceptin + Perjeta

Ado-trastuzumab Emtansine

CMF

DOW Module 1 Midpoint Quiz

Breast Cancer Treatment Insights Quiz

More Quizzes